Results 111 to 120 of about 414,372 (151)

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin. [PDF]

Diabetes Ther, 2022
Aravind SR, Singh KP, Mogylnytska L, Zalevskaya AG, Matyjaszek-Matuszek B, Wernicke-Panten K, Nguyên-Pascal ML, Pierre S, Rotthaeuser B, Kramer D, Mukherjee B.   +10 more
europepmc   +1 more source

Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial. [PDF]

Diabetes Metab J
Jang HN, Hong ES, Yang YS, Lee SO, Jang MJ, Mari A, Kwak SH, Park KS, Jang HC, Jung HS.   +9 more
europepmc   +1 more source

Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis. [PDF]

Cureus, 2022
Edina BC, Tandaju JR, Wiyono L.
europepmc   +1 more source

Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. [PDF]

Iran J Public Health
Niu YL, Zhang Y, Song ZY, Zhao CZ, Luo Y, Wang Y, Yuan J.   +6 more
europepmc   +1 more source

Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11. [PDF]

Diabetes Obes Metab, 2023
Evans M, Chubb B, Malkin SJP, Berry S, Lawson J, Hunt B.   +5 more
europepmc   +1 more source

Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factors. [PDF]

Medicine (Baltimore)
Xie M, Chen S, He Q.
europepmc   +1 more source

The Absorption of Needle-Free Insulin Aspart Through Jet Injector in Different Body Parts of Healthy Individuals. [PDF]

Front Endocrinol (Lausanne), 2022
Pan Q, Zhang L, Gu A, Yu D, Wang X, Zhou Y, Guo L.   +6 more
europepmc   +1 more source

The Effects of Subcutaneous Rapid-Acting Insulin Aspart in the Treatment of Mild and Moderate Diabetic Ketoacidosis in Children: A Prospective Study. [PDF]

Cureus
Talebi H, Razavi Z, Khazaei S.
europepmc   +1 more source

Correction to: Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries. [PDF]

Adv Ther, 2023
Fulcher GR, Akhtar S, Al-Jaser SJ, Medina J, Mohamed M, Nicodemus NA, Olsen AH, Singh KP, Kok A.   +8 more
europepmc   +1 more source

Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. [PDF]

Drug Des Devel Ther
Liu H, Cao H, Li T, Chen X, Yu H, Sun J, Yu Y.   +6 more
europepmc   +1 more source